52860 Federal Register / Vol. 73, No. 177 / Thursday, September 11, 2008 / Notices 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, e-mail your request, 

including your address, phone number, 

OMB number, and OS document 

identifier, to 

Sherette.funncoleman@hhs.gov, or call 

the Reports Clearance Office on (202) 

690–5683. Send written comments and 

recommendations for the proposed 

information collections within 30 days 

of this notice directly to the OMB Desk 

Officer; via fax to 202–395–6974. 

Proposed Project: Evaluation of HIV 

Prevention Program for Women—OMB 

No. 0990–New—Office on Women’s 

Health (OWH). 

Abstract: OWH is seeking a new 

clearance to conduct data collection 

activities associated with the three-year 

evaluation of HIV/AIDS prevention 

programs at minority institutions for 

college women. The evaluation will 

assess the effectiveness of gendercentered HIV prevention models 

employed to address the needs of 

college women attending six (6) 

Historically Black Colleges and 

Universities, four (4) Hispanic Serving 

Institutions, and two (2) Tribal Colleges 

and Universities. Evaluation data will 

assess the extent to which gender 

sensitive interventions employed by 

these institutions impact HIV/AIDS 

related knowledge, attitudes and risk 

behaviors. Results of the evaluation will 

identify the prevention outcomes for 

college women and the larger campus 

population. The program goals are to (1) 

identify effective methods to educate 

and increase awareness for prevention 

of HIV/AIDS and STD’s; (2) develop 

capacity for young, minority women to 

address prevention education on 

campus; (3) establish partnerships and 

student organizations to increase health 

education, risk reduction, counseling, 

HIV/STD testing and (4) to ensure that 

the education is culturally and 

linguistically appropriate for young, 

minority women. HIV intervention 

recipients will complete a survey at 

pretest, post-test and follow-up that 

assesses their HIV/AIDS knowledge, risk 

behaviors and gender specific attitudes. 

Student data will be submitted on a 

quarterly basis. Peer facilitators/health 

educators will participate in a yearly 

interview and project implementation 

staff will participate in individual 

interviews twice during each program 

year that assesses their experiences with 

the program. 

ESTIMATED ANNUALIZED BURDEN TABLE

Forms (if necessary) Type of respondent Number of respondents 

Number of responses per 

respondent 

Average burden 

hours per response 

Total burden 

hours 

Prevention Education: Pre-test Questionnaire .... Student ......................... 660 1 20/60 220 

Prevention Education: Post-test Questionnaire .. Student ......................... 660 1 20/60 220 

Prevention Education: Follow-up ........................ Student ......................... 660 1 20/60 220 

Process Interview: Program Directors ................ Program Directors ........ 14 2 1 .5 42 

Process Interview: Program Staff ....................... Program Staff ............... 12 2 45/60 18 

Program Staff ............... 12 55 15/60 165 

Process Interview: Peer Educators ..................... Peer Educators ............ 50 1 30/60 25 

Total ............................................................. ...................................... ........................ ........................ .......................... 910 

Seleda Perryman, 

Office of the Secretary, Paperwork Reduction 

Act Reports Clearance Officer. 

[FR Doc. E8–21119 Filed 9–10–08; 8:45 am] 

BILLING CODE 4150–33–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects 

Title: Communities Empowering 

Youth (CEY) Program Evaluation. 

OMB No.: 0970–0335. 

Description: This proposed 

information collection activity is to 

obtain information from Communities 

Empowering Youth (CEY) grantee 

agencies and the faith-based and 

community organizations working in 

partnership with them. The CEY 

evaluation is an important opportunity 

to examine the outcomes achieved 

through this component of the 

Compassion Capital Fund in meeting its 

objective of improving the capacity of 

faith-based and community 

organizations and the partnerships they 

form to increase positive youth 

development and address youth 

violence, gang involvement, and child 

abuse/neglect. The evaluation will be 

designed to assess changes and 

improvements in the structure and 

functioning of the partnership and the 

organizational capacity of each 

participating organization. The purpose 

of this request will be to revise the 

approved baseline instruments for 

follow-up data collection. 

Respondents: CEY grantees and the 

faith-based and community 

organizations that are a part of the 

partnership approved under the CEY 

grant. 


rmajette on PRODPC74 with NOTICES
Federal Register / Vol. 73, No. 177 / Thursday, September 11, 2008 / Notices 52861 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

hours per 

response 

(minutes) 

Total burden 

hours 

2009 ............................................................................................................... 464 1 45 348

Follow-up Survey.

2010 Follow-up Survey .................................................................................. 143 1 45 107 .25 

Estimated Total Annual Burden 

Hours: 455.25 

In compliance with the requirements 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Planning, Research 

and Evaluation, 370 L’Enfant 

Promenade SW., Washington, DC 20447. 

Attn: ACF Reports Clearance Officer. Email address: 

OPREinfocollection@acf.hhs.gov. All 

requests should be identified by the title 

of the information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents. Consideration will be 

given to comments and suggestions 

submitted within 60 days of this 

publication. 

Dated: September 4, 2008. 

Brendan C. Kelly, 

OPRE Reports Clearance Officer. 

[FR Doc. E8–21007 Filed 9–10–08; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0132] 

Agency Information Collection 

Activities; Announcement of Office of 

Management and Budget Approval; 

State Petitions for Exemption from 

Preemption 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a collection of information entitled 

‘‘State Petitions for Exemption from 

Preemption’’ has been approved by the 

Office of Management and Budget 

(OMB) under the Paperwork Reduction 

Act of 1995. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of Information 

Management (HFA–710), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–796–3794. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of June 16, 2008 (73 FR 

34024), the agency announced that the 

proposed information collection had 

been submitted to OMB for review and 

clearance under 44 U.S.C. 3507. An 

agency may not conduct or sponsor, and 

a person is not required to respond to, 

a collection of information unless it 

displays a currently valid OMB control 

number. OMB has now approved the 

information collection and has assigned 

OMB control number 0910–0277. The 

approval expires on August 31, 2011. A 

copy of the supporting statement for this 

information collection is available on 

the Internet at http://www.reginfo.gov/ 

public/do/PRAMain. 

Dated: September 4, 2008. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E8–21020 Filed 9–9–08; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2006–N–0178] (formerly 

Docket No. 2006N–0362) 

Draft Guidance for Industry and Food 

and Drug Administration Staff; Class II 

Special Controls Guidance Document: 

Absorbable Hemostatic Device; 

Availability; Reopening of Comment 

Period 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; reopening of comment 

period. 

SUMMARY: The Food and Drug 

Administration (FDA) is reopening until 

October 14, 2008, the comment period 

for a draft guidance entitled ‘‘Class II 

Special Controls Guidance Document: 

Absorbable Hemostatic Device.’’ The 

draft guidance describes a means by 

which the absorbable hemostatic device 

may comply with the requirements of 

special controls if it is reclassified. FDA 

is reopening the comment period to 

update comments and to receive any 

new information. Elsewhere in this 

issue of the Federal Register, FDA is 

reopening the comment period on a 

proposed rule to reclassify the 

absorbable hemostatic device from class 

III (premarket approval) into class II 

(special controls). 

DATES Although you can comment on 

any guidance at any time (see 21 CFR 

10.115(g)(5)), to ensure that the agency 

considers your comments on this draft 

guidance before it begins work on the 

final version of the guidance, submit 

written or electronic comments on the 

draft guidance October 14, 2008. 

ADDRESS: Submit written comments to 

the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments to http:// 

www.regulations.gov. See the 

SUPPLEMENTARY INFORMATION section for 

electronic access to the draft guidance 

document. 


rmajette on PRODPC74 with NOTICES